KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Interest Expenses (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Interest Expenses data on record, last reported at $4.8 million in Q4 2025.

  • For Q4 2025, Interest Expenses rose 15.18% year-over-year to $4.8 million; the TTM value through Dec 2025 reached $17.3 million, up 1.58%, while the annual FY2025 figure was $17.3 million, 1.58% up from the prior year.
  • Interest Expenses reached $4.8 million in Q4 2025 per IONS's latest filing, up from $4.2 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $4.8 million in Q4 2025 and bottomed at $1.6 million in Q1 2023.
  • Average Interest Expenses over 5 years is $3.2 million, with a median of $3.3 million recorded in 2021.
  • Peak YoY movement for Interest Expenses: crashed 79.33% in 2021, then surged 163.32% in 2023.
  • A 5-year view of Interest Expenses shows it stood at $2.2 million in 2021, then fell by 22.65% to $1.7 million in 2022, then soared by 163.32% to $4.6 million in 2023, then dropped by 8.05% to $4.2 million in 2024, then grew by 15.18% to $4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $4.8 million in Q4 2025, $4.2 million in Q3 2025, and $4.1 million in Q2 2025.